NCT03005327View on ClinicalTrials.gov

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 16, 2022

Study Completion Date

June 16, 2022

Conditions
WHIM Syndrome
Interventions
DRUG

X4P-001

Mavorixafor will be provided as either 25 mg or 100 mg capsules.

Trial Locations (2)

3065

St. Vincent's Hospital, Fitzroy

98195

University of Washington Medical Center, Seattle

Sponsors

Lead Sponsor

X4 Pharmaceuticals
All Listed Sponsors
lead

X4 Pharmaceuticals

INDUSTRY